dc.creator | López Cortés, Luis Fernando | es |
dc.creator | Viciana Fernández, Pompeyo | es |
dc.creator | Girón-González, José-Antonio | es |
dc.creator | Romero-Palacios, Alberto | es |
dc.creator | Márquez-Solero, Manuel | es |
dc.creator | Martínez-Pérez, Maria A. | es |
dc.creator | Mohamed-Balghata, Mohamed O. | es |
dc.date.accessioned | 2021-07-02T16:18:23Z | |
dc.date.available | 2021-07-02T16:18:23Z | |
dc.date.issued | 2014-05-16 | |
dc.identifier.citation | López Cortés, L.F., Viciana Fernández, P., Girón-González, J., Romero-Palacios, A., Márquez-Solero, M., Martínez-Pérez, M.A. y Mohamed-Balghata, M.O. (2014). Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population. PLoS ONE, 9 (5), art. n. 97262. | |
dc.identifier.issn | 1932-6203 (electrónico) | es |
dc.identifier.uri | https://hdl.handle.net/11441/115072 | |
dc.description.abstract | Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen
for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase
inhibitors (NRTIs). This multicenter study aimed to assess the efficacy of this combination in two scenarios: group A) subjects
without virologic failure on or no experience with non-nucleoside reverse-transcriptase inhibitors (NNRTIs) switched due to
adverse events and group B) subjects switched after a virologic failure on an efavirenz- or nevirapine-based regimen. The
primary endpoint was efficacy at 52 weeks analysed by intention-to-treat. Virologic failure was defined as the inability to
suppress plasma HIV-RNA to ,50 copies/mL after 24 weeks on treatment, or a confirmed viral load .200 copies/mL in
patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Two hundred eighty
seven patients were included. Treatment efficacy rates in group A and B were 88.0% (CI95, 83.9–92.1%) and 77.4% (CI95,
65.0–89.7%), respectively; the rates reached 97.2% (CI95, 95.1–99.3%) and 90.5% (CI95, 81.7–99.3), by on-treatment analysis.
The once-a-day ETV treatment was as effective as the twice daily dosing regimen. Grade 1–2 adverse events were observed
motivating a treatment switch in 4.2% of the subjects. In conclusion, ETV (once- or twice daily) plus two analogs is a suitable,
well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug
activity. | es |
dc.format | application/pdf | es |
dc.format.extent | 8 p. | es |
dc.language.iso | eng | es |
dc.publisher | Public Library of Science | es |
dc.relation.ispartof | PLoS ONE, 9 (5), art. n. 97262. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Etravirine Plus | es |
dc.subject | Non-nucleoside reverse-transcriptase inhibitors | es |
dc.subject | NNRTIs | es |
dc.title | Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0097262 | es |
dc.identifier.doi | 10.1371/journal.pone.0097262 | es |
dc.journaltitle | PLoS ONE | es |
dc.publication.volumen | 9 | es |
dc.publication.issue | 5 | es |
dc.publication.initialPage | art. n. 97262 | es |